Special Issue "Liver Cancers: From Bench to Bedside"
Deadline for manuscript submissions: closed (30 April 2021).
Liver cancers are a major issue in the oncosurgical community. The incidence of HCC and biliary tract cancers is steadily increasing due to the high prevalence of chronic hepatitis and the epidemic of non-alcoholic fatty liver disease.
Colorectal liver metastases (CLM) are the third most common type of cancer and the second most common cause of cancer-related deaths worldwide.
The so-called oncosurgical approach has been recognized as the gold standard in the treatment of CLM, pushing the limits of surgery especially in chemoresponse patients. The new discoveries in systemic therapy for primitive malignancies may also change the surgical indications for this disease.
This is the reason why the collaboration between surgeons and basic science researchers has been strengthened in recent decades.
Some of the new promising molecules in the treatment of HCC are the new two anti-PD-1 antibodies, namely nivolumab and pembrolizumab. Unfortunately, the low diffusion of their use in therapy is due to restrictions in their application by the European Union, which prevents confirmation of their validity. In the field of CLM, anti-PD-1 antibodies appear to be effective only in patients with microsatellite instability, which represent a small percentage of CLM patients.
This finding underlines the crucial relationship between the tumor and its immunological microenvironment.
The aim of this Special Issue is to share the latest insights into CLM derived from basic science findings, which can have an effective impact on surgical treatment of primitive and secondary liver lesions. Papers dealing with the development of new drugs or new information on the immunological interaction between the tumor and host are of particular interest.
Dr. Matteo Maria Cimino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- colorectal liver metastases
- hepatocellular carcinoma
- immunological microenvironment
- NK cells